Velocity CARE Council - Womens Health (small)

Delivering unparalleled reach and expertise for women's health clinical trials worldwide

participants enrolled in women’s health studies
women’s health trials supported
sites that can support women’s health trials with CARE Council oversight

Velocity has conducted trials that have led to more than 50 product approvals

The Women’s Health Council to Accelerate Research Excellence (CARE) champions effective operational, recruitment, and trial execution strategies for all Velocity sites conducting women’s health research.

Led by renowned OB/GYNs and women’s health specialists, the Women’s Health CARE Council integrates a profound understanding of women’s health concerns with Velocity’s extensive reach and innovative capabilities. From navigating the intricacies of hormonal changes and metabolic health to the challenges of reproductive health, there’s a heightened need for specialized, expert-led clinical research.

Before you begin your next clinical trial, let the Women’s Health CARE Council be your strategic ally. Council members can review your protocol and offer invaluable patient-centric insights to refine study designs. Moreover, the council will ensure Velocity sites are equipped with optimized recruitment strategies, comprehensive training, and quality oversight tailored to your research program. To strengthen your next women's health clinical trial, email

Reach and capabilities

  • 20+ sites with women’s health research experience
  • 50+ sites that can support women’s health trials with CARE Council oversight
  • Access to millions of patient lives
  • Conducted trials that have led to product approvals for women’s health therapies
  • World-class diversity and community engagement initiatives
  • Expertise in fetal health and pregnancy research

Women's Health CARE Council Leaders

Velocity's Women's Health CARE Council is led by distinguished physicians. The council leverages their vast experience in women's an maternal health research, alongside Velocity sites and staff that have supported thousands of trials and offer access to millions of patient lives.


Keith Vrbicky, MD

Having begun private practice in Norfolk, NE, in 1984, Dr. Vrbicky is a region-leading OB/GYN, the founder of Midwest Health Partners, and a highly regarded principal investigator. He has delivered more than 13,700 babies, and has maintained faculty appointments at Creighton University and the University of Nebraska Medical Center. Dr. Vrbicky co-authored the book Menopause Maze, and in 2006 he addressed the U.S. congressional subcommittee on Africa, Global Human Rights, and International Operations regarding the use of telemedicine. In May 2020, he enrolled the world’s first participant into Moderna’s Phase 2 COVID-19 vaccine trial. As an investigator, he is sought after for his extensive women’s health and general medical practice experience.

Headshot of William Beacham, MD

William Beacham, MD

A practicing OB/GYN and Principal Investigator for Velocity in Louisiana, Dr. Beacham has delivered more than 5,000 babies in his 40-year career. He has been a clinical professor at Tulane University School of medicine. His interests include obstetrical care, minimally invasive and robotic gynecologic surgery, endometriosis therapy, contraceptive therapy, and infertility. He has conducted studies for contraceptives, maternal RSV and GBS vaccines, infant and pediatric COVID-19 vaccines, and infant formulas.

Erica Haake, MD

Erica Haake, MD

Dr. Haake attended medical school at the University of Nebraska Medical Center and completed her residency at University of Oklahoma Health Sciences Center. She has participated in more than 2,700 deliveries. She started her post-residency clinical practice in OB/GYN in 2010 and became a Principal Investigator in Grand Island, NE, in 2020. Dr. Haake has conducted women’s health, maternal vaccine, and infant health studies. Her clinical interests include infertility, PCOS, contraception, STD prevention/treatment, cervical cancer screening, and vaccines.

CARE Council Logo_Horizontal White

A transformative model to confront the inefficiencies that plague clinical trials

1: Drug Development Technology. (2012). Clinical trial delays: America’s patient recruitment dilemma. | 2: Tufts Center for the Study of Drug Development. (2013). Impact report: 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. Vol. 15, No. 1. | 3: Kaitin, K. I. (2006). Fastest drug developers consistently best peers on key performance metrics. Tufts Center for the Study of Drug Development Impact Report, 8(5). | 4: Hess, J. (n.d.). Web-based patient recruitment: best opportunity to accelerate clinical trials.

of U.S. trials fail to meet enrollment timelines
of sites miss enrollment targets
daily operational losses for Sponsors for delayed trials
potential daily opportunity cost losses for delayed trials

Therapeutic and Specialty Population Expertise

When outcomes depend on the experience of your investigators and research staff, Velocity is the partner of choice

Trial experience

  • Bacterial Vaginosis
  • Contraception
  • Consumer Products
  • Cytomegalovirus Vaccine
  • Dysmenorrhea
  • Dyspareunia
  • Endometriosis
  • Fetal Health
  • Genital Herpes
  • Group B Streptococcus
  • High-Grade Squamous Intraepithelial Lesion (HSIL)
  • Hot Flash
  • Human Papillomavirus (HPV) Vaccines
  • Maternal Vaccine
  • Medical Devices
  • Menopause
  • Minimally-Invasive Surgical Procedures
  • Osteoporosis
  • Overactive Bladder
  • Polycystic Ovary Syndrome (PCOS)
  • Pre-Eclampsia
  • Pregnancy
  • PMS/PMDD (Premenstrual Syndrome/Premenstrual Dysphoric Disorder)
  • Sexual Dysfunction / Hypoactive Sexual Desire Disorder (HSDD)
  • Sexually-Transmitted Diseases
  • Urinary Incontinence
  • Uterine Fibroids
  • Vulvo-Vaginal Atrophy (VVA), Dryness

Specialty populations

  • Maternal
  • Newborns and Infants
  • Pediatrics, Adolescents
  • Geriatrics

Let's talk about your next trial